{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 458476502
| IUPAC_name = methyl ''N''-[(1''S'')-1-<nowiki/>{[(2''S'',3''S'')-3-hydroxy-4-[(2''S'')-2-[(methoxycarbonyl)amino]-3,3-dimethyl-''N'''-<nowiki/>{[4-(pyridin-2-yl)phenyl]methyl}butanehydrazido]-1-phenylbutan-2-yl]carbamoyl}-2,2-dimethylpropyl]carbamate
| image = Atazanavir structure.svg
| width = 180
| image2 = Atazanavir ball-and-stick.png
| width2 = 220

<!--Clinical data-->
| pronounce = {{IPAc-en|ˌ|æ|.|t|ə|.|ˈ|z|æ|.|n|ə|.|v|ɪər}}, {{respell|A|tə|ZA|nə-vir}}<ref>{{cite web |url=http://www.nlm.nih.gov/medlineplus/druginfo/meds/a603019.html |title=Atazanavir |work=[[MedlinePlus]] |publisher=[[National Institutes of Health]] |date=October 15, 2012 |accessdate=August 3, 2013 |deadurl=no |archiveurl=https://web.archive.org/web/20130802080019/http://www.nlm.nih.gov/medlineplus/druginfo/meds/a603019.html |archivedate=August 2, 2013 |df= }}</ref>
| tradename =  Reyataz, Evotaz, others<ref name=AHFS2016/>
| Drugs.com = {{drugs.com|monograph|atazanavir-sulfate}}
| MedlinePlus = a603019
| pregnancy_AU = B2
| pregnancy_US = B
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = By mouth

<!--Pharmacokinetic data-->
| bioavailability = 60-68%
| protein_bound = 86%
| metabolism = [[Liver]] ([[CYP3A4]]-mediated)
| elimination_half-life = 6.5 hours
| excretion = Fecal and [[kidney]]
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 198904-31-3
| ATC_prefix = J05
| ATC_suffix = AE08
| ATC_supplemental =  
| PubChem = 148192
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01072
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 130642
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = QZU4H47A3S
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D01276
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 37924
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1163
| NIAID_ChemDB = 057755
<!--Chemical data-->
| C=38 | H=52
| N=6 | O=7
| molecular_weight = 704.856 g/mol
| smiles = O=C(OC)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)Cc3ccc(c2ncccc2)cc3)C(C)(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = AXRYRYVKAWYZBR-GASGPIRDSA-N
}}

<!-- Definition and medical uses -->
'''Atazanavir''', sold under the trade name '''Reyataz''' among others, is an [[antiretroviral medication]] used to treat and prevent [[HIV/AIDS]].<ref name=AHFS2016/> It is generally recommended for use with other antiretrovirals.<ref name=AHFS2016/> It may be used for prevention after a [[needlestick injury]] or other potential exposure.<ref name=AHFS2016/> It is taken by mouth once a day.<ref name=AHFS2016/>

<!-- Side effects and mechanism -->
Common side effects include headache, nausea, [[jaundice|yellowish skin]], abdominal pain, [[insomnia|trouble sleeping]], and fever.<ref name=AHFS2016/> Severe side effects include rashes such as [[erythema multiforme]] and [[high blood sugar]].<ref name=AHFS2016/> Atazanavir appears to be safe to use during [[pregnancy]].<ref name=AHFS2016/> It is of the [[Protease inhibitor (pharmacology)|protease inhibitor]] (PI) class and works by blocking [[HIV protease]].<ref name=AHFS2016/>

<!-- History and culture -->
Atazanavir was approved for medical use in the United States in 2003.<ref name=AHFS2016>{{cite web|title=Atazanavir Sulfate|url=https://www.drugs.com/monograph/atazanavir-sulfate.html|publisher=The American Society of Health-System Pharmacists|accessdate=28 November 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161220123526/https://www.drugs.com/monograph/atazanavir-sulfate.html|archivedate=20 December 2016|df=}}</ref> It is on the [[World Health Organization's List of Essential Medicines]], the most effective and safe medicines needed in a [[health system]].<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|deadurl=no|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016|df=}}</ref> In the United States it is not available as a [[generic medication]].<ref name=Ric2015/> The wholesale cost in the [[developing world]] is about 15.72 USD per month.<ref>{{cite web|title=Atazanavir|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=ATA150T&s_year=2014&year=2014&str=150%20mg&desc=Atazanavir&pack=new&frm=TAB-CAP&rte=PO&class_code2=06%2E4%2E2%2E3&supplement=&class_name=%2806%2E4%2E2%2E3%29Protease%20inhibitors%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=28 November 2016}}</ref> As of 2015, the cost for a typical month of medication in the United States was more than 200 USD.<ref name=Ric2015>{{cite book|last1=Hamilton|first1=Richart|title=Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition|date=2015|publisher=Jones & Bartlett Learning|isbn=9781284057560|page=67}}</ref>

==Medical uses==
[[File:Atazanavir (Reyataz)200mg.jpg|thumb|Two Reyataz 200 mg capsules]]
Atazanavir is used in the treatment of HIV. The efficacy of atazanavir has been assessed in a number of well designed trials in ART-naive and ART-experienced adults.<ref name="atazanavir">{{cite journal|last1=Croom |first1=KF|last2= Dhillon|first2= S|last3= Keam |first3=SJ|journal=Drugs|date= 2009|volume=69|issue=8|pages=1107–1140|doi=10.2165/00003495-200969080-00009|title=Atazanavir: A Review of its Use in the Management of HIV-1 Infection|pmid=19496633}}</ref>

Atazanavir is distinguished from other PIs in that it has lesser effects on lipid profile and appears to be less likely to cause [[lipodystrophy]]. There may be some cross-resistant with other PIs.<ref name=AHFS2016/> When boosted with [[ritonavir]] it is equivalent in potency to [[lopinavir]] for use in ''salvage'' therapy in people with a degree of drug resistance, although boosting with ritonavir reduces the metabolic advantages of atazanavir.{{citation needed|date=December 2016}}

=== Pregnancy ===
Atazanavir is [[pregnancy category]] B in the United States, meaning that no evidence of harm has been found among pregnant women taking this medication. It is one of the preferred HIV medication to use in pregnant women who have not taken an HIV medication before.<ref name=":0">{{Cite web|url=https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/|title=What's New in the Guidelines? {{!}} Adult and Adolescent ARV Guidelines {{!}} AIDSinfo|website=AIDSinfo|access-date=2016-11-10|deadurl=no|archiveurl=https://web.archive.org/web/20161115104124/https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/|archivedate=2016-11-15|df=}}</ref> It was not associated with any birth defects among over 2,500 live births observed. Atazanavir resulted in a better cholesterol profile and confirmed that it is a safe option during pregnancy.<ref name=":0" />

==Contraindications==
Atazanavir is contraindicated in those with previous hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions). Additionally, atazanavir should not be given with alfuzosin, rifampin, irinotecan, lurasidone, pimozide, triazolam, orally administered midazolam, ergot derivatives, cisapride, St. John's wort, lovastatin, simvastatin, sildenafil, indinavir, or nevirapine.<ref name=":1">{{Cite web|url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021567s039,206352s004lbl.pdf|title=Reyataz Package Insert|last=|first=|date=September 2016|website=Drugs@FDA|publisher=Food and Drug Administration|access-date=November 10, 2016|deadurl=no|archiveurl=https://web.archive.org/web/20161111064629/http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021567s039,206352s004lbl.pdf|archivedate=November 11, 2016|df=}}</ref>

== Adverse effects ==
Common side effects include: nausea, [[jaundice]], rash, headache, abdominal pain, vomiting, insomnia, peripheral neurlogic symptoms, dizziness, [[myalgia|muscle pain]], diarrhea, depression and fever.<ref name=":1" /> [[Bilirubin]] levels in the blood are normally asymptomatically raised with atazanavir, but can sometimes lead to jaundice.

== Mechanism of action ==
Atazanavir binds to the active site HIV protease and prevents it from cleaving the pro-form of viral proteins into the working machinery of the virus.<ref>{{cite journal|date=9 November 2016|title=Atazanavir|url=https://www.drugbank.ca/drugs/DB01072|journal=DrugBank|deadurl=no|archiveurl=https://web.archive.org/web/20161109085814/https://www.drugbank.ca/drugs/DB01072|archivedate=9 November 2016|df=}}</ref> If the HIV protease enzyme does not work, the virus is not infectious, and no mature virions are made.<ref>{{cite journal|last2=Emini|first2=EA|last3=Schleif|first3=WA|last4=Davis|first4=LJ|last5=Heimbach|first5=JC|last6=Dixon|first6=RA|last7=Scolnick|first7=EM|last8=Sigal|first8=IS|date=1 July 1988|title=Active human immunodeficiency virus protease is required for viral infectivity.|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=85|issue=13|pages=4686–4690|issn=0027-8424|pmc=280500|pmid=3290901|first1=NE|last1=Kohl|doi=10.1073/pnas.85.13.4686}}</ref><ref>{{cite journal | last1 = Lv | first1 = Z | last2 = Chu | first2 = Y | last3 = Wang | first3 = Y | year = 2015 | title = HIV protease inhibitors: a review of molecular selectivity and toxicity.&nbsp; | url = | journal = HIV/AIDS – Research and Palliative Care| volume = 7 | issue = | pages = 95–104 | doi = 10.2147/HIV.S79956 |pmc=4396582}}</ref> 
The azapeptide drug was [[Discovery and development of HIV-protease inhibitors|designed]] as an analog of the peptide chain substrate that HIV protease would cleave normally into active viral proteins. More specifically, atazanavir is a structural analog of the transition state during which the bond between a phenylalanine and proline is broken.<ref>Graziani, Amy L (June 17, 2014). "HIV protease inhibitors". UpToDate.</ref><ref>{{cite journal|last1=Bold|first1=G|last2=Fässler|first2=A|last3=Capraro|first3=HG|last4=Cozens|first4=R|last5=Klimkait|first5=T|last6=Lazdins|first6=J|last7=Mestan|first7=J|last8=Poncioni|first8=B|last9=Rösel|first9=J|last10=Stover|first10=D|last11=Tintelnot-Blomley|first11=M|last12=Acemoglu|first12=F|last13=Beck|first13=W|last14=Boss|first14=E|last15=Eschbach|first15=M|last16=Hürlimann|first16=T|last17=Masso|first17=E|last18=Roussel|first18=S|last19=Ucci-Stoll|first19=K|last20=Wyss|first20=D|last21=Lang|first21=M|title=New Aza-Dipeptide Analogues as Potent and Orally Absorbed HIV-1 Protease Inhibitors:  Candidates for Clinical Development|journal=Journal of Medicinal Chemistry|date=August 1998|volume=41|issue=18|pages=3387–3401|doi=10.1021/jm970873c|pmid=9719591}}</ref> Humans do not have any enzymes that break bonds between phenylalanine and proline, so this drug will not target human enzymes.

==Formulations==
Atazanavir is available as a 150&nbsp;mg capsule, 200&nbsp;mg capsule, 300&nbsp;mg capsule, and 50&nbsp;mg oral powder packet.<ref name=":1" /> The 300&nbsp;mg capsule should reduce [[pill burden]], as one 300&nbsp;mg capsule may replace two 150&nbsp;mg capsules.<!--although a logical reason for the new formulation, this may constitute original research. Remove if felt best-->

==References==
{{Reflist|32em}}

{{HIVpharm}}

[[Category:Bristol-Myers Squibb]]
[[Category:HIV protease inhibitors]]
[[Category:Pyridines]]
[[Category:RTT]]
[[Category:World Health Organization essential medicines]]